Literature DB >> 10215666

Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.

A J Eshleman1, M Carmolli, M Cumbay, C R Martens, K A Neve, A Janowsky.   

Abstract

We characterized the effects of drugs on the uptake of [3H]neurotransmitter by and the binding of [125I](3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester ([125I]RTI-55) to the recombinant human dopamine (hDAT), serotonin (hSERT), or norepinephrine (hNET) transporters stably expressed in human embryonic kidney 293 cells. RTI-55 had similar affinity for the hDAT and hSERT and lower affinity for hNET (Kd = 1. 83, 0.98, and 12.1 nM, respectively). Kinetic analysis of [125I]RTI-55 binding indicated that the dissociation rate (k-1) was significantly lower for hSERT and the association rate (k+1) was significantly lower for hNET compared with the hDAT. The potency of drugs at blocking [3H]neurotransmitter uptake was highly correlated with potency at blocking radioligand binding for hDAT and hSERT. Substrates were more potent at the inhibition of [3H]neurotransmitter uptake than radioligand binding. The potency of drugs was highly correlated between displacement of [3H]nisoxetine (Kd = 6.0 nM) and [125I]RTI-55 from the hNET, suggesting that these radioligands recognize similar sites on the transporter protein. The correlation observed between inhibitory potency for uptake and binding of either ligand at the hNET was lower than correlations between uptake and binding for hDAT and hSERT. The present results indicate that the cocaine analog [125I]RTI-55 has unique binding properties at each of the transporters and that the use of recombinant transporters expressed by a single cell type can provide a powerful screening tool for drugs interacting with biogenic amine transporters, such as possible cocaine antagonists.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215666

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  71 in total

1.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

2.  The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.

Authors:  Kelli R Rodvelt; Clark E Oelrichs; Lucas R Blount; Kuo-Hsien Fan; Susan Z Lever; John R Lever; Dennis K Miller
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

Review 3.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Melittin initiates dopamine transporter internalization and recycling in transfected HEK-293 cells.

Authors:  Dove J Keith; Katherine Wolfrum; Amy J Eshleman; Aaron Janowsky
Journal:  Eur J Pharmacol       Date:  2012-06-05       Impact factor: 4.432

Review 5.  Substrate and drug binding sites in LeuT.

Authors:  Ajeeta Nyola; Nathan K Karpowich; Juan Zhen; Jennifer Marden; Maarten E Reith; Da-Neng Wang
Journal:  Curr Opin Struct Biol       Date:  2010-06-16       Impact factor: 6.809

6.  Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.

Authors:  Ronald J Lukas; Ana Z Muresan; M Imad Damaj; Bruce E Blough; Xiaodong Huang; Hernán A Navarro; S Wayne Mascarella; J Brek Eaton; Syndia K Marxer-Miller; F Ivy Carroll
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

7.  Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters.

Authors:  Amy J Eshleman; Shanthi Nagarajan; Katherine M Wolfrum; John F Reed; Tracy L Swanson; Aaron Nilsen; Aaron Janowsky
Journal:  Psychopharmacology (Berl)       Date:  2018-11-05       Impact factor: 4.530

Review 8.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

9.  Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells.

Authors:  M Bliziotes; A Eshleman; B Burt-Pichat; X-W Zhang; J Hashimoto; K Wiren; C Chenu
Journal:  Bone       Date:  2006-08-01       Impact factor: 4.398

10.  Development of serotonin transporter reuptake inhibition assays using JAR cells.

Authors:  Ann M Decker; Bruce E Blough
Journal:  J Pharmacol Toxicol Methods       Date:  2018-03-16       Impact factor: 1.950

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.